In a report published earlier today, Jefferies upgraded Johnson & Johnson JNJ from a Hold to Buy rating and raised its price target from $68 to $72.
Jefferies stated, “Management has beaten expectations by re-engineering the financing of the Synthes merger. Instead of a dilutive stock issuance followed by a share buyback program, the company has borrowed stock through an accelerated share repurchase agreement, which transforms the transaction into an accretive deal. The net effect is to raise our mid-term earnings estimates by 4-5% and we have upgraded the shares to Buy from Hold as a result.”
JNJ closed at $63.08 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in